Scilex Holding Company/DE Form 4 (Nov. 25, 2022)

Summary

This Form 4 reports that on November 25, 2022 Sorrento Therapeutics, Inc., a 10% owner of Scilex Holding Company/DE [SCLX], bought 46,172 warrants to purchase common stock. The warrants carry an $11.5 exercise price and expire 11/10/2027; the weighted average purchase price was $0.4374 per warrant, with individual prices ranging from $0.37 to $0.45, inclusive. Following the purchase, Sorrento owns 4,265,776 warrants directly. The form is signed by Henry Ji, Ph.D., as President, Chief Executive Officer and Chairman of the Board of Sorrento Therapeutics, Inc., on 11/25/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Sorrento Therapeutics, Inc. (Last) (First) (Middle) 4955 DIRECTORS PLACE (Street) SAN DIEGO CA 94303 (City) (State) (Zip) | Sorrento Therapeutics, Inc. | (Last) | (First) | (Middle) | 4955 DIRECTORS PLACE | SAN DIEGO | CA | 94303 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Scilex Holding Company/DE [ SCLX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below) | Director | X | 10% Owner | Officer (give title below) | Other (specify below)
3. Date of Earliest Transaction
 (Month/Day/Year) 11/25/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Warrants to Purchase Common Stock | $ 11.5 | 11/25/2022 | P | 46,172 | 11/10/2022 | 11/10/2027 | Common Stock | 46,172 | $ 0.4374 (1) | 4,265,776 | D
Explanation of Responses:
1. The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.37 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price.
Remarks:
/s/ Henry Ji, Ph.D., President, Chief Executive Officer and Chairman of the Board, Sorrento Therapeutics, Inc. | 11/25/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_SRNE_4_filed2022-11-25_0000899243-22-037015.xml

Size

15,809 bytes

SHA-256

978b55d905f4ec4363bc93f9be6f9fad8f019c5915d9bd8eb7d40ddba17b8828

Our copy

SEC_SRNE_4_filed2022-11-25_0000899243-22-037015.xml

Original

www.sec.gov